Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of tenofovir drug transporters in the context of HBV: Is there an impact?

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Jun 2024

Cusato J, Manca A, Palermiti A, Mula J, Antonucci M, Chiara F, De Nicolò A, Lupia Tommaso, Stroffolini Giacomo, Boglione L, D'Avolio A

Abstract excerpt

BACKGROUND: Current treatments for chronic hepatitis B management include orally administered nucleos(t)ide analogues, such as tenofovir (TDF), which is an acyclic adenine nucleotide analogue used both in HBV and human immune deficiency virus (HIV). The course of HBV infection is mainly dependent on viral factors, such as HBV genotypes, immunological features and host genetic variables, but a few data are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Membrane Transport Proteins

Share to Multidrug Resistance-Associated Proteins

Share to Pharmacogenetics

Share to Tenofovir

Source

Identifiers

PMID: 38713940
DOI: 10.1016/j.biopha.2024.116678

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of tenofovir drug transporters in the context of HBV: Is there an impact?PMID 38713940Read ↗

Pharmacogenetics of Tenofovir TreatmentSemantic proximity Read ↗

Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines.Semantic proximity Read ↗

Influence of <i>ABCC2</i> and <i>ABCC4</i> Polymorphisms on Tenofovir Plasma Concentrations in Thai HIV-Infected PatientsSemantic proximity Read ↗

A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection.Semantic proximity Read ↗

ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment.Semantic proximity Read ↗

Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.Semantic proximity Read ↗

ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.Semantic proximity Read ↗

Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.Semantic proximity Read ↗

Pharmacogenetic determinants of tenofovir diphosphate and lamivudine triphosphate concentrations in people with HIV/HBV coinfection.Semantic proximity Read ↗

Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population.Semantic proximity Read ↗

Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.